S&P 500
5,940.46
-0.4%
-23.14
DJI
42,677.24
-0.3%
-114.83
NASDAQ
$19,142.71
-0.4%
-$72.75
Bitcoin
106,568.00
+1.2%
+1,272.35
AAPL
$206.73
-1.0%
-$2.05
AMZN
$204.08
-1.0%
-$2.08
GOOG
$165.14
-1.6%
-$2.73
META
$636.43
-0.6%
-$4.00
MSFT
$457.90
-0.2%
-$0.97
NVDA
$134.22
-1.0%
-$1.34
TSLA
$343.52
+0.4%
+$1.43
Neuren Pharmaceuticals (ASX: NEU)
A$12.92
(0.8%)
A$0.10
Price as of May 21, 2025, 2:00 a.m. ET
Neuren Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Neuren Pharmaceuticals Company Info
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its products include Pipeline, Trofinetide, and NNZ-2591. The company was founded on December 17, 2001 and is headquartered in Camberwell, Australia.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.